Fig 1.
AF, atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; ESRD, end-stage renal disease; LC, liver cirrhosis.
Table 1.
Clinical characteristics in NOAC users.
Fig 2.
Time-specific proportions of high and low adherence patients for NOACs.
NOAC, non-vitamin K antagonist oral anticoagulant; M, month; Y, year; Apix/Dabi, apixaban or dabigatran; Edox/Riva, edoxaban or rivaroxaban; *p value <0.05 compared with Edox/Riva users; †p value < 0.001 compared with dabigatran users; ‡p value < 0.05 compared with dabigatran users.
Fig 3.
Time-specific PDC for each NOAC.
PDC, proportion of days covered; NOAC, non-vitamin K antagonist oral anticoagulant; M, month; Y, year; Apix/Dabi, apixaban or dabigatran; Edox/Riva, edoxaban or rivaroxaban; *p value < 0.001 compared with Edox/Riva users; †p value < 0.001 compared with dabigatran users; ‡p value < 0.01 compared with dabigatran users.
Fig 4.
The cumulative incidence curves of clinical outcomes for patients with high and low adherence to NOACs: Composite outcome, stroke, acute myocardial infarction (AMI), and death.
CI, confidence interval.
Fig 5.
Comparative clinical outcomes of each NOAC in high and low adherence groups.
NOAC, non-vitamin K antagonist oral anticoagulant; HR, hazard ratio; CI, confidence interval; AMI, acute myocardial infarction.
Table 2.
Event and event rate in NOAC users in the overall study population and the comparative risks for clinical outcomes of patients with low adherence compared with those with high adherence in propensity score-matched population.